Completed PHASE2 INTERVENTIONAL NCT00001599

Pilot Study of Thalidomide to Treat Sjogren's Syndrome

Pilot Study of Thalidomide for Sjogren's Syndrome

Sponsor: National Institute of Dental and Craniofacial Research (NIDCR)

Conditions Sjogren's Syndrome Xerostomia

Interventions Thalidomide

Updated 5 times since 2017 Last updated: Mar 3, 2008 Started: May 31, 1997 Completion: Jun 30, 2002

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Sjogren's Syndrome and Xerostomia and is currently completed. National Institute of Dental and Craniofacial Research (NIDCR) leads this study, which shows 5 recorded versions since 1997 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

May 1997

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Institute of Dental and Craniofacial Research (NIDCR)

Data source: National Institutes of Health Clinical Center (CC)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bethesda, United States